Join us on Tuesday, April 22nd for the next event in our OmniAb Webinar Series, “xPloration: Simplifying Deep Antibody Mining for Maximum Impact.” Our Vice President of Discovery Systems, Bob Chen, PhD, will present how OmniAb’s xPloration platform delivers superior screening and

OmniAb Announces Two New Appointments to its Board of Directors investors.omniab.com/investors/news…

Happy Earth Day! OmniAb is thrilled to celebrate our dedicated OASIS environmental committee members and employees who generously volunteered their time last weekend to clean up and support local communities and the environment. hashtag#EarthDay2025

OmniAb to Participate in Five Upcoming Investor Conferences investors.omniab.com/investors/news…

OmniAb is headed to New Orleans for the ISCT, International Society for Cell and Gene Therapy 2025 meeting. We're excited to hear about the global breakthroughs in cell and gene therapy from the industry's leading researchers and clinicians. Be sure to drop by Booth #938

OmniAb Introduces the xPloration® Partner Access Program investors.omniab.com/investors/news…

OmniAb Reports First Quarter 2025 Financial Results and Business Highlights investors.omniab.com/investors/news…

OmniAb is headed to Boston for the 2025 PEGS Summit! Join us Tuesday, May 13th at 12:15pm for a presentation with our VP of Discovery Systems, Bob Chen, PhD, on “xPloration®: Simplifying Deep Antibody Mining for Maximum Impact.” We’ll see you there! pegsummit.com/cancer-antibod…

The OmniAb team is so excited to kick off the week in Boston for the 2025 PEGS Summit! Join us in the exhibit hall at booth 305 and mark your calendars for tomorrow’s session to hear about the latest in single B-cell screening and antibody discovery. Learn more:

Join us this week @PEGSBoston at Booth 305! We'll be talking about our suite of antibody discovery technologies and high-throughput single B-cell screening platform. Let’s connect! #PEGSummit omniab.com/partnerships/c…

OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit investors.omniab.com/investors/news…

🏆 Congratulations to OmniAb , Inc. — winner of the Best of Show Award at #PEGSummit 2025! Their xPloration® Partner Access Program captured attendee votes by a landslide for its innovation and impact. Thanks to all who participated, and congrats again to the OmniAb team!

OmniAb CEO Matt Foehr shares his reflections from PEGS Summit Boston 2025 — a week filled with groundbreaking science, meaningful connections, and OmniAb's xPloration winning Best of Show! Thank you to everyone who joined us #PEGSummit!

Teva Pharmaceutical Industries, Ltd. announced celiac disease candidate TEV-53408 has been granted Fast Track Designation by the US FDA. TEV-53408 is an OmniAb-derived anti-IL-15 antibody for the treatment of people with celiac disease on a gluten-free diet. TEV-53408 is

Early results from Johnson & Johnson’s trispecific antibody (JNJ-79635322) show promising response in heavily pretreated multiple myeloma patients #ASCO2025 #OmniAb jnj.com/media-center/p…

Join OmniAb’s SVP of Antibody Technologies, Christel Iffland, PhD, for a presentation at the Antibody Engineering & Therapeutics Europe conference next week on, “Building Multispecifics from in vivo Derived Antibody Domains and Alternative Scaffolds.” We hope to see you there!

Meet the OmniAb team in Incheon, South Korea for World ADC Asia 2025! We are excited to hear from the industry’s global leaders in ADC innovation. Let’s connect, join us at booth 24. omniab.com/partnerships/c… #WorldADC

OmniAb to Report Second Quarter 2025 Financial Results on August 6 investors.omniab.com/investors/news…

We’re honored to share that OmniAb has been nominated for BioSpace’s Best Places to Work in Life Sciences! This recognition reflects the passion, innovation, and teamwork that define our culture, and we couldn’t be more proud of our amazing team. Please take a moment to vote and

OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights investors.omniab.com/investors/news…